SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the ...

So despite the success of HIV drugs and PrEP, precarious health-care systems and high drug costs mean we can’t rely on them to bring an end to the ongoing global HIV pandemic.

The WHO recommends lenacapavir, an HIV prevention drug, as global funding cuts threaten efforts to combat the epidemic. Learn about its impact and challenges.

A newly approved twice-yearly injection for HIV prevention has rejuvenated hope in the national and global drive to end HIV/Aids as a public health threat by 2030. Lenacapavir, the groundbreaking ...

The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. But deep cuts to health initiatives could hinder the rollout. Lenacapavir not ...

UNAIDS called the program a “lifeline” for countries with high HIV rates, and said that it supported testing for 84.1 million people, treatment for 20.6 million, among other initiatives.

Global HIV gains at risk as funding crisis sparks urgent call to action Severe cuts to international aid are disrupting lifesaving HIV services in vulnerable countries, with UNAIDS warning of ...

South Africa has played a historic, global role in scientific research, from COVID-19 vaccines to HIV.

The 2025 Global AIDS Update warns a historic funding crisis risks undoing decades of progress unless countries make radical changes to HIV programmes, funding Scientific research, public health ...

A new U.N. AIDS agency report says the sudden withdrawal of U.S. funding has caused a “systemic shock” to the global effort against AIDS and HIV.